Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook
Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company specializing in innovative vaccines, is gaining momentum with strong financial results and pipeline progress...